MME and acute lymphoblastic leukemia: ZNF384r-ALL also frequently displays a distinct immunophenotype compared with the majority of other BCP-ALL subtypes; the immunophenotypically distinctZNF384r-ALL cases do not express (or only weakly express) CD10 marker but express myeloid markers CD13 or CD33 (or both) and may be even classified as mixed-phenotype acute leukemias on the basis of EGIL (European Group for the Immunological Characterization of Leukaemias) or WHO criteria30,32–34.